EUCTR2006-003427-37-IT进行中（未招募）1 期
Sirolimus treatment in patients with autosomal dominant polycystic kidney disease renal efficacy and safety - ND
IST. DI RICERCHE FARMACOLOG. M. NEGRI0 个研究点目标入组 16 人开始时间: 2006年12月27日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Age 18 years - Clinical and ultrasound diagnosis of ADPKD - GFR 40 ml/min/1.73 m2 estimated by the 4 variable MDRD equation - Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Diabetes - Overt proteinuria urinary protein excretion rate 1g/24 hours or abnormal urinalysis suggestive of concomitant, clinically significant glomerular disease - Urinary tract lithiasis, infection or obstruction - Cancer - Psychiatric disorders and any condition that might prevent full comprehension of the purposes and risks of the study - Pregnancy, lactation or child bearing potential and ineffective contraception estrogen therapy in post menopausal women should not be stopped
研究者
相似试验
进行中（未招募）
1 期
Pulsed oral sirolimus in autosomal dominant polycystic kidney diseaseAutosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and uncontrolled proliferation of innumerable epithelial-lined cysts that stem from renal tubular cells, which compress and/or destroy vital renal tissue with a gradual decline in renal function, and terminal kidney failure with the need for renal reaplacement therapy. As yet, other than supportive care there is no viable therapy.MedDRA version: 20.0Level: LLTClassification code 10036046Term: Polycystic kidney, autosomal dominantSystem Organ Class: 100000004850EUCTR2012-000550-60-ATMedizinische Universität Wien, Klinische Abteilung für Nephrologie und Dialyse, Universitätsklinik für Innere Medizin 368
已完成
不适用
Study of Efficacy of Sirolimus in Patients with Activated PI3Kdelta SyndromeActivated PI3Kdelta SyndromeJPRN-UMIN000023046Department of Human Genetics National Center for Child Health and Development5
进行中（未招募）
1 期
Effects of Sirolimus on disease progression in patients with Autosomal Dominant Polycystic Kidney Disease and severe renal insufficiency - SIRENA IIAutosomal Dominant Polycystic Kidney Disease (ADPKD)MedDRA version: 9.1 Level: LLT Classification code 10010428 Term: Congenital cystic kidney diseaseEUCTR2007-005047-21-ITIST. DI RICERCHE FARMACOLOG. M. NEGRI40
已完成
不适用
Clinical study on efficacy and safety of sirolimus against epileptic seizures of focal cortical dysplasia type IIPatients with epilepsy with focal cortical dysplasia type 2JPRN-UMIN000030962Hokkaido University Hospital2
尚未招募
不适用
Sirolimus with reduced calcineurin inhibitor regimen in ABO incompatible kidney transplantatioKCT0005271Asan Medical Center80